Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.
Even a small share of the massive market for weight loss drugs could lead to a significant increase in this company's share price.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.